- Home
- BCDA vs CELZ Comparison
BCDA vs CELZ Comparison
Compare BCDA & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CELZ
- Stock Information
- Founded
- BCDA N/A
- CELZ 1998
- Country
- BCDA United States
- CELZ United States
- Employees
- BCDA N/A
- CELZ N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CELZ Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- CELZ Health Care
- Exchange
- BCDA Nasdaq
- CELZ Nasdaq
- Market Cap
- BCDA 11.3M
- CELZ 10.4M
- IPO Year
- BCDA N/A
- CELZ N/A
- Fundamental
- Price
- BCDA $1.39
- CELZ $4.09
- Analyst Decision
- BCDA Strong Buy
- CELZ
- Analyst Count
- BCDA 1
- CELZ 0
- Target Price
- BCDA $25.00
- CELZ N/A
- AVG Volume (30 Days)
- BCDA 306.5K
- CELZ 49.1K
- Earning Date
- BCDA 11-12-2025
- CELZ 11-07-2025
- Dividend Yield
- BCDA N/A
- CELZ N/A
- EPS Growth
- BCDA N/A
- CELZ N/A
- EPS
- BCDA N/A
- CELZ N/A
- Revenue
- BCDA N/A
- CELZ $6,000.00
- Revenue This Year
- BCDA N/A
- CELZ N/A
- Revenue Next Year
- BCDA N/A
- CELZ N/A
- P/E Ratio
- BCDA N/A
- CELZ N/A
- Revenue Growth
- BCDA N/A
- CELZ N/A
- 52 Week Low
- BCDA $1.00
- CELZ $1.69
- 52 Week High
- BCDA $3.20
- CELZ $6.90
- Technical
- Relative Strength Index (RSI)
- BCDA 42.69
- CELZ 66.08
- Support Level
- BCDA $1.40
- CELZ $3.35
- Resistance Level
- BCDA $1.52
- CELZ $4.23
- Average True Range (ATR)
- BCDA 0.11
- CELZ 0.27
- MACD
- BCDA 0.02
- CELZ 0.05
- Stochastic Oscillator
- BCDA 32.82
- CELZ 86.15
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.